UroToday.com· @urotoday · X·· 2 天前评分70
正文 · 机器翻译
Capivasertib + Abiraterone 对比 Placebo + Abiraterone 在 PTEN 缺陷 #mHSPC 患者中的疗效：CAPItello-281 更新总生存期数据。由 @fizazi_karim @GustaveRoussy 报告。#ESMO26 文字报道由 @zklaassen_md 提供 > https://bit.ly/4iDxpio #ProstateCancer @myESMO
350 浏览 · 2 赞 · 4 转发 · 0 回复
会议摘要
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281
https://esmocongress.esmo.org来源：UroToday.com · x.com